How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1581-1583

  Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cytokine; JAK2; JAK2 inhibitor; Myelofibrosis

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; ITF 2357; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME INHIBITION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; MYELOFIBROSIS; NONHUMAN; PRIORITY JOURNAL;

ALLELES; HUMANS; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS;

EID: 70249107079     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.001     Document Type: Note

References (10)

1. Mesa R., and Gale R.P. Hypothesis: how do jak2-inhibitors work in myelofibrosis. Leuk Res 33 (2009) 1156-1157
2. Pardanani A. Jak2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22 (2008) 23-30
3. Pardanani A., GotlIb J., Jamieson C., Cortes J., Talpaz M., and Stone R.M. A phase i study of TG101348, an orally bioavailable JAK-selective inhibitor, in patients with myelofibrosis. Blood 112 (2008) 97A
4. Verdstovsek S., Kantarjian H.M., Pardanani A.D., Thomas D., Cortes J., and Mesa R.A. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis and post-polycythemia/essential thrombocythemia myelofibrosis. Blood (2008) 1762A
5. Vannucchi A.M., Migliaccio A.R., Paoletti F., Chagraoui H., and Wendling F. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease. Semin Oncol 32 (2005) 365-372
6. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., Uzan G., Jasmin C., and Martyre M.C. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112 (2008) 3026-3035
7. Jiang L., Li Z., and Rui L. Leptin stimulates both JAK2_dependent and JAK2-independent signaling pathways. J Biol Chem (2008)
8. Vainchenker W., Dusa A., and Constantinescu S.N. Jaks in pathology: role of janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 19 (2008) 385-393
9. Rambaldi A., Dellacasa C.M., Salmoiraghi S., Spinelli O., Ferrari M.L., and Gattoni E. A phase 2a study of the histone-deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Blood 112 (2008) 100A
10. Guerini V., Barbui V., Spinelli O., Salvi A., Dellacasa C., and Carobbio A. The histone deacetylase inhibitor ITF 2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22 (2008) 740-747